

Nexstim Plc

("Nexstim")

The decisions of the Board of Directors

Company Announcement, Helsinki, 31th March 2016 at 6 PM

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that the Board of Directors of Nexstim Plc. has today, in the meeting that took place after the Annual General Meeting, elected the members of the Board Committees as follows:

The chairman of the Audit Committee shall be Juliet Thompson and the members shall be Juha Vapaavuori and Ekaterina Smirnyagina.

The chairman of the Remuneration committee shall be Ken Charhut and the members shall be Johan Christenson and Martin Jamieson.

For the time being, the following members shall continue in the Nomination Committee: the chairman shall be Staffan Lindstrand and the members shall be Sami Tuhkanen and Jos Peeters. The Board Chairman, Martin Jamieson, shall participate in the Nomination Committee meetings.

The following members of the Board of Directors of Nexstim Plc: Johan Christenson, Ekaterina Smirnyagina and Juha Vapaavuori and the members of the Nomination Committee: Staffan Lindstrand, Sami Tuhkanen and Jos Peeters have announced that they will not be accepting Board fees from the Company. The above mentioned Board members will be receiving travelling reimbursements according to the decision of the Annual General Meeting.

Commenting on the announcement, Martin Jamieson, Chairman of the Board, said: "Nexstim has understood and dealt with some very interesting issues. We are now clear about the way forward, one being the financing of the Company which will be concluded before the end of the third quarter 2016"

NEXSTIM PLC Janne Huhtala, Chief Executive Officer

For further information please visit www.nexstim.com or contact:

Nexstim +358 (0)40 8615046 Janne Huhtala, Chief Executive Officer

UB Securities Ltd (Certified Adviser)

Consilium Strategic Communications Mary-Jane Elliott / Ivar Milligan / Laura Thornton janne.huhtala@nexstim.com

+358 (0)9 2538 0246

+44 (0)20 3709 5700 nexstim@consilium-comms.com

About Nexstim Plc

Nexstim

Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT[®]). Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit <u>www.nexstim.com</u>.